Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
12.57
+0.72 (6.08%)
Mar 4, 2026, 4:00 PM EST - Market closed

Entrada Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
453394650505424535
Market Cap Growth
-4.90%-39.42%28.76%18.87%-20.60%-
Enterprise Value
200.91148.8288.87220.83261.68243.5
Last Close Price
12.5710.2817.2915.0913.5217.12
PE Ratio
--2.9610.29-75.45-4.48-2.10
PS Ratio
17.5315.483.083.91--
PB Ratio
1.391.291.522.082.001.79
P/TBV Ratio
1.701.391.572.061.990.36
P/FCF Ratio
--3.04-14.533.76-4.39-9.64
P/OCF Ratio
--3.06-15.633.61-4.53-10.51
EV/Sales Ratio
7.905.851.371.71--
EV/EBITDA Ratio
--0.975.69-687.94-2.74-4.87
EV/EBIT Ratio
--0.946.14-69.84-2.69-4.76
EV/FCF Ratio
--1.15-6.461.65-2.71-4.39
Debt / Equity Ratio
0.170.170.140.280.120
Debt / EBITDA Ratio
-0.33-0.331.17-212.55-0.27-
Debt / FCF Ratio
-0.39-0.39-1.320.51-0.27-
Net Debt / Equity Ratio
-0.80-0.80-0.84-1.17-0.77-0.97
Net Debt / EBITDA Ratio
1.591.59-7.10883.921.715.82
Net Debt / FCF Ratio
1.891.898.07-2.111.685.25
Asset Turnover
0.060.060.420.3600
Quick Ratio
12.1412.1410.732.258.5943.32
Current Ratio
12.5312.5311.152.339.5544.46
Return on Equity (ROE)
-39.13%-39.13%19.56%13.54%-37.01%-30.19%
Return on Assets (ROA)
-35.17%-35.17%9.32%-2.24%-34.86%-29.27%
Return on Invested Capital (ROIC)
-211.29%-211.29%48.50%-10.60%-336.34%-1114.73%
Return on Capital Employed (ROCE)
-37.61%-37.61%11.79%-1.17%-36.75%-30.14%
Earnings Yield
-32.25%-33.75%9.72%-1.33%-22.34%-47.66%
FCF Yield
-29.07%-32.92%-6.88%26.59%-22.78%-10.37%
Buyback Yield / Dilution
-0.23%-0.23%-15.85%-4.17%-0.11%-35.85%
Updated Feb 26, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q